Tyr593
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr593  -  FAM129B (human)

Site Information
PIDWGEEysNSGGGG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 25299904
Available spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 , 6 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 )
Disease tissue studied:
brain cancer ( 1 ) , glioblastoma ( 1 ) , glioma ( 1 ) , breast cancer ( 2 ) , lung cancer ( 3 , 4 , 5 , 6 ) , non-small cell lung cancer ( 3 , 4 , 6 ) , non-small cell lung adenocarcinoma ( 3 , 4 , 5 ) , non-small cell large cell lung carcinoma ( 3 ) , non-small cell squamous cell lung carcinoma ( 5 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
EGFR (human) ( 1 )
Kinases, in vitro:
EGFR (human) ( 1 )
Treatments:
AG1478 ( 1 ) , EGF ( 1 )

Downstream Regulation
Effects of modification on FAM129B:
molecular association, regulation ( 1 ) , phosphorylation ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , signaling pathway regulation ( 1 )
Induce interaction with:
HRas (human) ( 1 )

References 

1

Ji H, et al. (2016) EGFR phosphorylates FAM129B to promote Ras activation. Proc Natl Acad Sci U S A 113, 644-9
26721396   Curated Info

2

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Moritz A (2009) CST Curation Set: 7286; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info